BridgeMD
Studying the LAIV induced Immune respOnse in the Nasopharynx of young children.
EU CTIS ID: 2024-513933-18-00
What this study is testing
Identifying mucosal surrogates of protection following intranasal LAIV in children. Shedding of the LAIV is used as a surrogate for susceptibility to infection, with the expectation that the first dose of LAIV induces variable levels of immunity that confer protection against shedding of the second dose.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age between two and seven years old
- Parents ability and willingness to adhere to protocol-specified procedures, including availability of a freezer at home to store samples. Donating blood is optional as this is a secondary endpoint.
You likely can't join if
- Recipient of any influenza vaccine (both LAIV or IIV) in the same or a previous flu-season.
- Recipient of any other vaccine within one month prior to inclusion-date.
- Meeting one or more contraindications for the Fluenz vaccine as stated in paragraph 6.3 of the protocol.
- Substantial language barrier of either potential subject or parent. Participants and their parents are asked to self-collect samples during this trial, therefore instructions need be given and adequately understood.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.